| Project/Area Number |
16K14632
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
杉山 弘 京都大学, 理学研究科, 教授 (50183843)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | RUNX / 遺伝子スイッチ / CROX / 担癌マウスモデル / 発現制御 / 癌 / 免疫学 / シグナル伝達 / 薬理学 |
|---|
| Outline of Final Research Achievements |
GVHD and Allergy can be regulated by Cluster regulation of RUNX Transcription family:CROX. Ref.Sci Rep. 2018 Apr23;8(1):6423.RUNX1 regulates KIT expression and is a novel therapeutic target in human mast-cell diseases.J Immunol May 1, 2017,Allergy is effectively regulated by CROX through down-regulate C-kit signaling,and through inhibit the mast cells releasing Histamine.
|
